Arcutis Q1 net loss $64.3M ($1.27/sh); cash $344.8M; roflumilast PDUFA July 29

Arcutis Biotherapeutics, Inc.

2022-Q1 EPS reported -$1.27

Net loss widened to $64.3M ($1.27 per share) from $36.0M ($0.76) in Q1 2021.
Cash & securities $344.8M at Mar 31, down from $388.6M at Dec 31 2021; ATM added $14.5M.
PDUFA action date July 29, 2022 for roflumilast cream in plaque psoriasis; commercial prep underway.
Completed enrollment of pivotal Phase 3 trials for roflumilast foam in seborrheic dermatitis and scalp/body psoriasis.
R&D spend $40.6M vs $21.6M; G&A $22.0M vs $14.5M, driven by clinical and launch preparations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.